Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Latanoprost 0.005% Ophthalmic Solution

Phase 2

PPolyActiva Pty Ltd

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Glaucoma, Open-AngleActive, not recruiting

Glaucoma, Open-AnglePhase 2

Active, not recruiting

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Glaucoma, Open-Angle

NCT06964191

Clinical

Trials by Indication[1]

Glaucoma, Open-Angle1 trial

A Phase 2 Randomized, Multi-center, Parallel, Active-controlled Clinical Study to Evaluate the Safety and Efficacy of Intracameral PA5108 Ocular Implants in Patients With Primary Open-angle Glaucoma, or Ocular Hypertension

Active, not recruiting·PPolyActiva Pty Ltd·Phase 2·NCT06964191·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Latanoprost 0.005% Ophthalmic Solution. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Latanoprost 0.005% Ophthalmic Solution. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — PolyActiva Pty Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: PPolyActiva Pty Ltd

Related News